Akèy › Melanom › New York › New York City
Etid klinik pou Melanom nan New York City, NY
38 etid pou Melanom ap chèche patisipan nan sit nan ak bò kote New York City (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Memorial Sloan Kettering (Melanoma/NSCLC), New York
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 2
- Memorial Sloan Kettering Hospital, New York
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
Ap rekriteFaz 2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
Ap rekriteFaz 3
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Ap rekrite
- Weill Cornell Medicine, New York
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
Ap rekriteFaz 2
- Local Institution - 0170, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors
Ap rekriteFaz 1
- NYU Langone, New York
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Hospital, New York
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
Ap rekriteFaz 2
- Memorial Sloan Kettering Cancer Center, New York
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
Ap rekrite
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
Ap rekriteFaz 1/2
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
- Mount Sinai Hospital, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- ak 2 plis
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ap rekriteFaz 1/2
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
Ap rekriteFaz 2
- NYU Langone Health, New York
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Ap rekriteFaz 1/2
- Weill Cornell Medicine - New York Presbyterian Hospital, New York
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Ap rekriteFaz 1/2
- NYU Langone Health, New York
- Icahn School of Medicine At Mount Sinai Prime, New York
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Ap rekriteFaz 1/2
- Call for Information (Investigational Site 0031), New York
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- Weill Medical College of Cornell University, New York
- Memorial Sloan Kettering Cancer Center, New York
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 2
- USA04-0, New York
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Ap rekriteFaz 1/2
- Perlmutter Cancer Center at NYU Langone Health, New York
- Memorial Sloan-Kettering Cancer Center, New York
- Columbia University, New York
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
Ap rekriteFaz 1/2
- Memorial Sloan Kettering Cancer Center, New York
Neoadjuvant Darovasertib in Primary Uveal Melanoma
Ap rekriteFaz 3
- Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave, New York
- Northwell Health Cancer Institute, New York
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Ap rekriteFaz 1
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- Columbia University Medical Center, New York
- Memorial Slone Kettering Cancer Center, New York
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Ap rekriteFaz 2/3
- Memorial Sloan Kettering Cancer Center, New York
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
Ap rekriteFaz 3
- Memorial Sloan Kettering Cancer Center, New York
ACTengine® IMA203 Combined With mRNA-4203
Ap rekriteFaz 1
- Memorial Sloan Kettering Cancer Center, New York
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
Ap rekriteFaz 2
- NYU Langone Health, New York
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Research Site 107, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, New York
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
Ap rekrite
- Memorial Sloan Kettering Cancer Center, New York
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- Weill Cornell Medicine-New York-Presbyterian Hospital, New York
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Ap rekriteFaz 1/2
- NYU Langone Health, New York
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Ap rekrite
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
- Memorial Sloan Kettering Cancer Center, New York
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Ap rekriteFaz 1/2
- Memorial Sloan-Kettering Cancer Center, New York
Etid Melanom nan lòt vil
- Houston, TX59 etid
- Los Angeles, CA34 etid
- Nashville, TN33 etid
- Pittsburgh, PA31 etid
- Boston, MA26 etid
- Philadelphia, PA23 etid
- San Francisco, CA22 etid
- Columbus, OH21 etid
- St. Louis, MO21 etid
- Salt Lake City, UT21 etid
- Durham, NC21 etid
- Atlanta, GA21 etid
Lòt etid nan New York City
- Kansè nan tete136 etid
- Kansè Poumon ki pa ti selil121 etid
- Kansè (tout kalite)109 etid
- Kansè pwostat103 etid
- Kansè Metastatik93 etid
- Kansè kolorektal78 etid
- Kansè ovè69 etid
- Kansè poumon60 etid
- Myelom Miltip60 etid
- Kansè pankreyas60 etid
- Kansè Endomèt52 etid
- Leksemi mieloïd egi51 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.